返回
公司介紹
董事會
管理團隊
合作伙伴
企業榮譽
專利布局
納基奧侖賽
認證醫療機構名單
創新支付
研發管線
學術發表
公司新聞
產品新聞
媒體報道
企業文化
招賢納士
Risk of hepatitis B reactivation is controllable in patients with B-cell lymphoma receiving anti-CD19 CAR T cell therapy
Phase 1 Results of CNCT19: CD19 CAR Constructed of a New Anti-CD19 Chimeric Antigen Receptor in Relapsed or Refractory Acute Lymphoblastic Leukemia.
The Risk of Hepatitis B Reactivation Is Controllable in Patients with Concomitant Hepatitis B Virus Infection during Chimeric Antigen Receptor T-Cell Therapy